{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:38:44Z","timestamp":1790091524022,"version":"4.0.1"},"reference-count":47,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"Institutional Development","award":["U54GM115677"],"award-info":[{"award-number":["U54GM115677"]}]},{"name":"Institutional Development","award":["P20GM125507"],"award-info":[{"award-number":["P20GM125507"]}]},{"name":"National Institute of General Medical Sciences of the National Institutes of Health"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Misuse"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/10826084.2023.2205492","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T09:50:39Z","timestamp":1683021039000},"page":"1038-1045","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Benzodiazepine Dose Intensity among Patients Concurrently Prescribed Buprenorphine in Rhode Island"],"prefix":"10.1080","volume":"58","author":[{"given":"Eric P.","family":"Borrelli","sequence":"first","affiliation":[{"name":"University of Rhode Island College of Pharmacy, Kingston, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-5768","authenticated-orcid":false,"given":"Jeffrey","family":"Bratberg","sequence":"additional","affiliation":[{"name":"University of Rhode Island College of Pharmacy, Kingston, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-9615","authenticated-orcid":false,"given":"Benjamin D.","family":"Hallowell","sequence":"additional","affiliation":[{"name":"Rhode Island Department of Health, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kogut","sequence":"additional","affiliation":[{"name":"University of Rhode Island College of Pharmacy, Kingston, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.01.013"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.918197"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(91)90023-4"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.12.011"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.1.58"},{"issue":"8","key":"CIT0006","first-page":"53","volume":"103","author":"Borrelli E. P.","year":"2020","journal-title":"Rhode Island Medical Journal (2013)"},{"key":"CIT0007","unstructured":"Buprenorphine [package insert]. (2019). Hikma Pharmaceuticals USA Inc."},{"key":"CIT0008","unstructured":"Centers for Medicare and Medicaid Services. (2016). Concurrent use of opioids and benzodiazepines in a Medicare Part D population. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/Downloads\/Concurrent-Use-of-Opioids-and-Benzodiazepines-in-a-Medicare-Part-D-Population-CY-2015.pdf"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0211"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2007.0036"},{"key":"CIT0011","first-page":"85","volume-title":"An introduction to generalized linear models","author":"Dobson A. J.","year":"2002","edition":"2"},{"issue":"3","key":"CIT0012","first-page":"1","volume":"71","author":"Dowell D.","year":"2022","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g445"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2019.06.007"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1122-4"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109680"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22106"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.2.169"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.4097\/kja.19087"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.05.015"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-016-3740-0"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2015.09.003"},{"key":"CIT0023","unstructured":"Lake, J., Frydrich, V., Gonzales, V., Martinez Alonso, E. & LaFleur, J. (2017). Concurrent use of benzodiazepines and stimulants. Utah Medicaid DUR Report. https:\/\/medicaid.utah.gov\/pharmacy\/drugutilization\/files\/Criteria%20Review%20Documents\/2017\/2017.08%20Concurrent%20stimulants%20and%20benzodiazepines.pdf"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.24095\/hpcdp.28.4.01"},{"issue":"8","key":"CIT0025","first-page":"648","volume":"19","author":"Liu Y.","year":"2013","journal-title":"American Journal of Managed Care,"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.07.024"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2019.0128"},{"key":"CIT0028","unstructured":"National Institute on Drug Abuse. (2020). Common comorbidities with substance use disorders research report. National Institute on Drug Abuse. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK571451\/"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1111\/add.14886"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2698"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.02.007"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.93913859.x"},{"key":"CIT0033","unstructured":"Rhode Island Department of Health. (2023). Prescription drug monitoring program. https:\/\/health.ri.gov\/healthcare\/medicine\/about\/prescriptiondrugmonitoringprogram\/"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S150253"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20040376"},{"key":"CIT0036","unstructured":"Sparks, A., Cohen, A., Albright, B., Barkett, P., Caldeiro, R., Chau, J., Gary, M., Greene, D., Kavanagh, M., Nguyen, K., Painter, K., Parrish, R., Robinson, K., Salama, N., Stedronsky, A., Sturgis, M. & Vinh, D. (2022). Benzodiazepine and z-drug safety guideline. Kaiser Permanente. https:\/\/wa.kaiserpermanente.org\/static\/pdf\/public\/guidelines\/benzo-zdrug.pdf"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2014.003"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.2011.01185.x"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.02.010"},{"key":"CIT0040","unstructured":"Suboxone (buprenorphine-naloxone film) [package insert]. (2021). Indivior Inc."},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.10.014"},{"key":"CIT0042","unstructured":"United States Food and Drug Administration. (2017). FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: Careful medication management can reduce risks. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-urges-caution-about-withholding-opioid-addiction-medications"},{"issue":"10","key":"CIT0043","first-page":"64","volume":"105","author":"Weidele H. R.","year":"2022","journal-title":"Rhode Island Medical Journal (2013)"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.357"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081174"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0530-4"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.02.019"}],"container-title":["Substance Use &amp; Misuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10826084.2023.2205492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:17:21Z","timestamp":1684171041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10826084.2023.2205492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/10826084.2023.2205492"],"URL":"https:\/\/doi.org\/10.1080\/10826084.2023.2205492","relation":{},"ISSN":["1082-6084","1532-2491"],"issn-type":[{"value":"1082-6084","type":"print"},{"value":"1532-2491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}